Perseus Proteomics Inc. (TYO:4882)
Japan · Delayed Price · Currency is JPY 141.00
-4.00 (-2.76%)
Aug 19, 2026, 3:30 PM JST
Perseus Proteomics Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 147.22 | 135 | 120 | 100 | 94 | 71 | |
Revenue Growth | 19.71% | 12.50% | 20.00% | 6.38% | 32.39% | 5.97% |
Cost of Revenue | 20.73 | 19 | 16 | 13 | 7 | 5 |
Gross Profit | 126.49 | 116 | 104 | 87 | 87 | 66 |
Selling, General & Admin | 872.58 | 288 | 336 | 366 | 290 | 231 |
Research & Development | -15.17 | 573 | 594 | 616 | 494 | 308 |
Operating Expenses | 857.42 | 861 | 930 | 982 | 784 | 539 |
Operating Income | -730.93 | -745 | -826 | -895 | -697 | -473 |
Interest & Investment Income | 5.24 | 5 | 1 | - | - | - |
Currency Exchange Gain (Loss) | 24.15 | 13 | -2 | 16 | 7 | 9 |
Other Non Operating Income (Expenses) | -7.5 | 47 | -3 | -1 | - | -19 |
EBT Excluding Unusual Items | -709.04 | -680 | -830 | -880 | -690 | -483 |
Asset Writedown | -33.67 | -37 | -72 | -153 | -95 | -117 |
Other Unusual Items | - | - | - | -70 | - | 2 |
Pretax Income | -742.71 | -717 | -902 | -1,103 | -785 | -598 |
Income Tax Expense | 1.93 | 1 | 2 | 1 | 1 | 1 |
Net Income | -744.64 | -718 | -904 | -1,104 | -786 | -599 |
Net Income to Common | -744.64 | -718 | -904 | -1,104 | -786 | -599 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 15 | 15 | 14 | 12 | 12 | 11 |
Shares Outstanding (Diluted) | 15 | 15 | 14 | 12 | 12 | 11 |
Shares Change | 5.10% | 4.47% | 21.05% | 0.24% | 6.94% | 57.10% |
EPS (Basic) | -48.06 | -48.17 | -63.35 | -93.65 | -66.84 | -54.47 |
EPS (Diluted) | -48.06 | -48.17 | -63.35 | -93.65 | -66.84 | -54.47 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -662 | -794 | -976 | -728 | -509 |
Free Cash Flow Per Share | - | -44.41 | -55.65 | -82.80 | -61.91 | -46.29 |
Gross Margin | 85.92% | 85.93% | 86.67% | 87.00% | 92.55% | 92.96% |
Operating Margin | -496.49% | -551.85% | -688.33% | -895.00% | -741.49% | -666.20% |
Profit Margin | -505.80% | -531.85% | -753.33% | -1104.00% | -836.17% | -843.66% |
Free Cash Flow Margin | - | -490.37% | -661.67% | -976.00% | -774.47% | -716.90% |
EBITDA | -731.16 | -744.62 | -824 | -892 | -692 | -471 |
D&A For EBITDA | -0.23 | 0.38 | 2 | 3 | 5 | 2 |
EBIT | -730.93 | -745 | -826 | -895 | -697 | -473 |